Cargando…
Bridging communities in the field of nanomedicine
An early dialogue between nanomedicine developers and regulatory authorities are of utmost importance to anticipate quality and safety requirements for these innovative health products. In order to stimulate interactions between the various communities involved in a translation of nanomedicines to c...
Autores principales: | Halamoda-Kenzaoui, Blanka, Baconnier, Simon, Bastogne, Thierry, Bazile, Didier, Boisseau, Patrick, Borchard, Gerrit, Borgos, Sven Even, Calzolai, Luigi, Cederbrant, Karin, Di Felice, Gabriella, Di Francesco, Tiziana, Dobrovolskaia, Marina A., Gaspar, Rogério, Gracia, Belén, Hackley, Vincent A., Leyens, Lada, Liptrott, Neill, Park, Margriet, Patri, Anil, Roebben, Gert, Roesslein, Matthias, Thürmer, René, Urbán, Patricia, Zuang, Valérie, Bremer-Hoffmann, Susanne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6597901/ https://www.ncbi.nlm.nih.gov/pubmed/31051191 http://dx.doi.org/10.1016/j.yrtph.2019.04.011 |
Ejemplares similares
-
Mapping of the available standards against the regulatory needs for nanomedicines
por: Halamoda‐Kenzaoui, Blanka, et al.
Publicado: (2018) -
Main trends of immune effects triggered by nanomedicines in preclinical studies
por: Halamoda-Kenzaoui, Blanka, et al.
Publicado: (2018) -
Methodological needs in the quality and safety characterisation of nanotechnology-based health products: Priorities for method development and standardisation
por: Halamoda-Kenzaoui, B., et al.
Publicado: (2021) -
Future perspectives for advancing regulatory science of nanotechnology-enabled health products
por: Halamoda-Kenzaoui, Blanka, et al.
Publicado: (2022) -
Toxic effects of nanomaterials for health applications: How automation can support a systematic review of the literature?
por: Halamoda‐Kenzaoui, Blanka, et al.
Publicado: (2021)